System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 1 citation

PubMed: 39941433 DOI: 10.3390/jcm14030762

Hypercoagulability in Tuberculosis: Pathophysiological Mechanisms, Associated Risks, and Advances in Management-A Narrative Review.

J Clin Med 14(3)

Authors: Denisa Maria Mitroi, Mara Amalia Balteanu, Ramona Cioboata, Silviu Gabriel Vlasceanu, Ovidiu Mircea Zlatian, Oana Maria Catana, Adina Andreea Mirea, Gabriel Florin Razvan Mogos, Ionela Rotaru, Viorel Biciusca

Affiliations

  • Doctoral School, University of Medicine and Pharmacy, 200349 Craiova, Romania.
  • Department of Pulmonology, Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.
  • Pneumology Department, University of Medicine and Pharmacy, 200349 Craiova, Romania.
  • Department of Physiology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Microbiology Department, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Department of Oral-Dental Prevention, University of Medicine and Pharmacy, 200349 Craiova, Romania.
  • Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Department of Hematology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Abstract

Tuberculosis (TB) induces a hypercoagulable state characterized by systemic inflammation, endothelial dysfunction, and alterations in the coagulation and fibrinolytic pathways. This review explores the pathophysiological mechanisms underlying hypercoagulability in TB, including increased pro-inflammatory cytokine release, endothelial damage, platelet activation, and reduced anticoagulant and fibrinolytic activity. These factors contribute to an elevated risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), which complicate TB prognosis and treatment. The potential role of adjunctive anti-inflammatory therapies, such as vitamin D, NSAIDs, corticosteroids, and anti-platelet agents, is highlighted as a strategy to mitigate systemic inflammation and reduce thrombotic risks in patients with TB. The challenges of anticoagulation therapy, particularly in managing the interactions between anti-TB medications and traditional anticoagulants, are discussed, along with the potential of novel oral anticoagulants (NOAs) as alternatives. We also address therapy of hypercoagulability in TB within resource-limited settings which requires low-cost diagnostics, accessible anticoagulation options, adjunctive therapies, and preventive strategies integrated into existing healthcare systems. Effective risk stratification and individualized management strategies are vital for reducing the morbidity and mortality associated with thrombotic complications in TB.

MeSH

Disease Management, Anticoagulants, Embolism, Thrombophilia, Tuberculosis, Therapeutics, Blood Platelets